Related references
Note: Only part of the references are listed.Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M. Wattenberg et al.
BRITISH JOURNAL OF CANCER (2020)
O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
M Tempero et al.
ANNALS OF ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma
Kenneth H. Yu et al.
CANCERS (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer
Michael L. Pearl et al.
GYNECOLOGIC ONCOLOGY (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
Gayatri Premasekharan et al.
CANCER LETTERS (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Kenneth H. Yu et al.
CLINICAL CANCER RESEARCH (2014)
Role of solute carrier transporters in pancreatic cancer: a review
Radmila Lemstrova et al.
PHARMACOGENOMICS (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients
Janice Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer
Pamela L. Paris et al.
CANCER LETTERS (2009)
Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer
Tina Fan et al.
GYNECOLOGIC ONCOLOGY (2009)
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases
Lei Xu et al.
MOLECULAR CANCER RESEARCH (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Guo Wei et al.
CANCER CELL (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins
Roger G. Deeley et al.
PHYSIOLOGICAL REVIEWS (2006)
The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research
MM Gottesman et al.
FEBS LETTERS (2006)
Identifying differentially expressed genes using false discovery rate controlling procedures
A Reiner et al.
BIOINFORMATICS (2003)
A gene expression database for the molecular pharmacology of cancer
U Scherf et al.
NATURE GENETICS (2000)
Share Paper
